Clinical Trial Search

Primary: Objective Response Rate (ORR) — 2; 0 Participants

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Objective Tumor Response — 12.2; 31.4 percentage of participants

Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants

Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341

Primary: Tumor Response — 23.4 Percentage of participants

Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants

Primary: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events — 1; 9; 20; 9 Participants

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Median Time to Progression — 7.2 months

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: PFS — 29.8 Months

Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months

Primary: Progression-free Survival (PFS) — 7.2; 13.0 months

Primary: Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 3; 15; 5 Participants

Primary: The Percentage of Patients Who Survive Progression Free for at Least 6 Months — 23 percentage of participants

Primary: Four Cycle Progression-free Survival Rate — 8 Participants

Primary: Clinical Benefit Rate [CBR] — 12 Participants

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients

Primary: Participant Responses — 2; 8; 4; 6 participants

Primary: Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or…

Primary: Objective Tumor Response — 21; 32; 17; 1 participants

Primary: Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST) — 12.4; 8.4 Months — p=<0.0001

Primary: Number of Participants With Treatment Success — 23 Participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants